Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave Ignite Study at the Annual Meeting of the American Diabetes Association

Orexigen Therapeutics OREX announced today that two Contrave® (naltrexone HCI and bupropion HCI) abstracts will be presented at the upcoming annual meeting of the American Diabetes Association being held in Boston June 5 – 9, 2015 at the Boston Convention and Exposition Center. The abstracts are the first presentations of data from the randomized, open-label Ignite Study, which was designed to provide additional information regarding Contrave in combination with a behavioral modification program, compared to patients who received diet and exercise advice but who did not receive Contrave. Consistent with current labeling for recently approved anti-obesity medications, the 242 patients randomized into the study were required to achieve a certain amount of weight loss (at least 5% at week 16) and to not have a meaningful increase in blood pressure to remain on medication. The primary endpoint for this trial was change in body weight after 26 weeks in the per-protocol population. Secondary endpoints included the percentage of patients achieving at least 5% and 10% weight loss, waist circumference, lipids, and measures of glucose homeostasis, as well as a number of other key measures. Details on the presentation times are as follows: Date/Time: June 7, 2015, 12:00 – 2 PM Title: 1287-P. Efficacy of Naltrexone/Bupropion, Administered as Recommended in Clinical Practice, Compared with Usual Care Authors: Thomas Wadden, Brandon Walsh, Amy E. Halseth, Kevin Shan, Kenneth Fujioka Date/Time: June 7, 2015, 12:00 – 2 PM Title: 1194-P. Improvement in Patient-Assessed Quality of Life, Eating Behavior, and Sexual Function after 26 Weeks of Naltrexone/Bupropion Compared with Usual Care Authors: Kenneth Fujioka, Brandon Walsh, Amy E. Halseth, Kevin Shan, Thomas Wadden